Davis Polk advised Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co. and Morgan Stanley & Co. LLC as joint book-running managers on an SEC-registered offering by Celgene Corporation of $500 million aggregate principal amount of its 2.250% senior notes due 2019, $1 billion aggregate principal amount of its 3.625% senior notes due 2024 and $1 billion aggregate principal amount of its 4.625% senior notes due 2044.
Headquartered in Summit, New Jersey, Celgene Corporation is a global integrated biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory-related diseases.
The Davis Polk corporate team included partner Richard D. Truesdell, Jr. and associates Christopher M. Bezeg and Zachary N. Lupu. Associate Jansen A. S. Thurmer provided intellectual property advice. Partner Neil Barr provided tax advice. All members of the Davis Polk team are based in the New York office.
